Abstract
This report presents a remarkable and unusual case of extrapulmonary small cell carcinoma (EPSCC) occurring in the prostate of a 77-year-old male patient with a previous history of prostate adenocarcinoma and multiple metastases. EPSCC is a highly aggressive form of cancer that often results in unfavorable survival outcomes, posing significant challenges in terms of management due to the absence of established treatment protocols. Despite receiving standard treatment including bicalutamide and leuprorelin, the patient's condition showed no improvement. Consequently, the medical team made the decision to administer a carboplatin-etoposide chemotherapy regimen along with durvalumab, drawing upon the efficacy observed in similar treatment approaches for small cell carcinoma of the lung. This case highlights the critical need for further research and clinical trials to establish optimal treatment strategies for EPSCC affecting the prostate. By enhancing our understanding of this rare malignancy, we can potentially improve patient outcomes and develop targeted therapies tailored to its aggressive nature.